Transfection
ScreenFect™A is a cationic lipid transfection reagent combining high transfection efficiency with low cell toxicity.
Applications
Offering a simple one-step protocol which combines both transfection and plating of cells, ScreenFectA can be used to transfect cells with DNA or siRNA.
Transfection can typically be detected in 24-48h and the low cell toxicity of ScreenFectA eliminates the need to change media post-transfection.
Benefits
Efficient transfection for DNA and siRNA
ScreenFect A is a new lipid based transfection reagent for use with plasmid DNA or siRNA. Using Click Chemistry a library of newly developed cationic liposomes were synthesised and then screened in vitro to determine transfection efficiency. When transfecting a GFP expressing plasmid into HEK 293T cells ScreenFect A demonstrated the best transfection efficiency and exhibits minimal toxicity.
Simple One-Step Protocol
ScreenFect A offers a simple one-step protocol which combines both transfection and plating of cells. Cells from the logarithmic growth phase are detached from their routine culture vessel and suspended in medium. Diluted ScreenFect A and DNA/siRNA complex is then added to the cell suspension and mixed gently by pipetting before transfer to the plate.
Transfection results can typically be detected in 24-48h. The low cell toxicity of ScreenFect A eliminates the need to change media post-transfection and since ScreenFect A can be added directly to media containing serum and antibiotics transfection protocols can be fuss-free.
Transfection Efficiency that Stands Out from the Crowd
ScreenFect A demonstrated transfection efficiency equal to or better than other commercially available transfection reagents. Seen below are HEK 293 cells transfected with 75ng/well of GFP-expressing plasmid in a 96 well culture plate.
Efficient siRNA Delivery
ScreenFect A mediated siRNA delivery has also been demonstrated. The efficiency of GAPDH siRNA transfection using ScreenFect A and a competitor product was compared using HeLa, MCF7 and A431 cell lines. Cells were transfected with 3nM/well GAPDH siRNA in 96 wells efficiency assessed by mRNA quantification.
Suppression of low-density lipoprotein receptor (LDL-R) - related protein 6 (LRP-6) using siRNA was investigated in HEK 293 cells following transfection with different reagents. Cells were transfected in 96 well plates with 2 nM/well LRP6 siRNA targeting LRP-6. ScreenFect A mediated delivery of the siRNA resulted in greated protein knock-down than competitor products.
Transfection Success with Wide Range of Cell Lines
The ScreenFect A formula has been successfully used to transfect DNA or siRNA into a broad range of cells with high efficiency. Not just commonly used cell lines such as HeLa, HepG2 and Cos-7 but also blood cells (macrophages, THP-1 and RAW264.7), microglia and primary cell cultures. Success has even been reported with stem cell cultures (mouse embryonic stem cells (MES) and embryonic fibroblasts (MEF)). Seen below ScreenFect A mediated transfection of GFP in MES, demonstration 60% efficiency.
Fuss-Free Transfection
High transfection efficiency
Low toxicity – no need to change medium after transfection
Serum compatible
for use with DNA and siRNA
Publications
-
Li et al, 2012: A biomimetic lipid library for gene delivery through thiol-yne click chemistry
-
Fischer et al, 2013: Breaking limitation of complex culture media: functional non-viral miRNA delivery into pharmaceutical production cell lines
-
Liu et al, 2013: Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1
-
Enlund et al, 2014: Establishment of lipofection for studying miRNA function in human adipocytes
-
Diefenbacher et al, 2014: The LIM domain protein nTRIP6 recruits the mediator complex to AP-1-regulated promoters
